Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Perjeta
Pharma
ASCO: AZ, Daiichi flex Enhertu muscle in 2 cancers
Enhertu and Perjeta significantly lowered the risk of progression or death by 44% compared with THP in first-line HER2-positive breast cancer.
Angus Liu
Jun 2, 2025 8:00am
Roche bolsters Perjeta's case with ten-year breast cancer data
May 13, 2025 11:23am
Enhertu drives strong efficacy in first-line breast cancer
Apr 21, 2025 10:12am
Roche settles UPenn patent lawsuit over breast cancer drugs
Mar 14, 2025 3:00pm
BMS' Opdivo hits more approvable goal in early NSCLC
Nov 8, 2021 10:35am
AZ, Daiichi start Enhertu head-to-head trial in 1L breast cancer
Jun 14, 2021 10:35am
